SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus

Aventus ($AVT.X) is trending amid community excitement, with many highlighting its low market cap and potential for significant gains, especially as it's listed on Coinbase. Discussions revolve around breaking resistance levels and the possibility of a new exchange listing acting as a catalyst. Some users also point to its underlying technology and partnerships as reasons for its potential.

Brewski

$BREWSKI.X is trending as users celebrate 'American spirit' and brotherhood, frequently pairing it with meme-related coins. The community is highlighting potential whale activity and positioning it as the 'next great American runner'. Conversations also suggest a potential connection to current political trends.

Ankr is a Web3 decentralized infrastructure provider that helps developers, dapps, and stakers easily interact with multiple blockchains. It allows you to create DApps using API and RPC, staking on Ankr Earn, and use customized blockchain solutions for businesses.

Ankr Network

Ankr Network ($ANKR.X) is trending amidst mixed community sentiment, with some touting its infrastructure role in Web3 and the potential of its new L1 Neura blockchain for developers, while others express strong dissatisfaction, labeling it a long-term scam and criticizing its price performance compared to other crypto assets. The core debate revolves around the token's utility and the team's ability to deliver tangible value for holders versus its promise as a foundational element for the decentralized web. Discussions also involve broader themes around infrastructure versus hype-driven crypto investments.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor ($NVTS) is trending amid community discussions around a potential breakout and anticipation for news related to its partnership with Nvidia ($NVDA). Some traders speculate about a possible acquisition, while others are focused on insider trading activity and the impact of the new CEO, Chris Allexandre, on the company's future direction in AI data centers.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending due to concerns about production timelines for their Gravity SUV and the overall company's profitability, reflected in negative sentiment from some investors. Despite a recent commercial spot during an NFL game and news of accelerated Gravity SUV production, some community members express skepticism about Lucid's financial future and the effectiveness of the reverse stock split. Discussions also involve potential future funding from Saudi PIF and comparisons to other EV manufacturers like Tesla and Rivian.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta ($KTA.X) is trending amid anticipation for its mainnet launch and excitement surrounding its potential to revolutionize traditional finance. Community members highlight Keeta's anchor technology and partnerships as key drivers for unifying blockchains. The recent listing on exchanges like Coinbase is also fueling positive sentiment, with some suggesting it will replace other blockchains.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar is trending as investors digest mixed signals, including commentary around tariffs and a potential shift towards energy project ownership. Community members are actively debating the impact of government policies and comparing CSIQ's valuation to peers. Bullish sentiment highlights the company's potential in a growing solar market, while bears express concern over debt and profitability.

Memecoin on Injective taken over by the community.

Nonja

$NONJA.X is trending as community members highlight its strong ties to the Injective ecosystem and anticipate significant gains. The conversation is driven by Injective's increasing traction and potential ETF, with many believing $NONJA.X offers leveraged exposure to $INJ's growth. Community members emphasize $NONJA.X's unique features, such as its strong community, burned liquidity, and potential for high returns.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD is trending due to recent financial guidance updates and the completed acquisition of Melinta Therapeutics, with the community actively discussing the potential impacts of the acquisition and future revenue projections. Some are concerned about potential executive stock sales, while others are optimistic about the company's growth and the potential for a short squeeze. Discussions also revolve around DefenCath's adoption rates and potential CMS policy changes.

Pump.fun

$PUMP.X is trending as traders discuss its potential, recent website updates, and community takeover of creator rewards, driving bullish sentiment. Conversations revolve around potential breakout points, with community members calling for it to reach penny status. The coin is associated with the meme coin launchpad Pump.fun on the Solana network.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Surgery Partners (SGRY) Q2 Earnings and Revenues Beat Estimates

Surgery Partners (SGRY) delivered earnings and revenue surprises of +6.25% and +0.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Danaher (DHR) Q2 Earnings and Revenues Top Estimates

Danaher (DHR) delivered earnings and revenue surprises of +9.76% and +1.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Surgery Partners, Inc. (SGRY) on Tuesday announced that it has <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.surgerypartners.com/news-releases/news-release-details/surgery-partners-inc-and-bain-capital-conclude-discussions">decided</a> to reject Bain Capital Private Equity’s proposal to take the healthcare services company private. Following the announcement, SGRY stock slumped 13% by Tuesday morning.Surgery Partners, headquartered in Brentwood, Tennessee, said that the firm’s independent committee determined that the company’s prospects to deliver long-term growth and value creation as an independent publicly traded company exceeded the value of the proposal by Bain Capital, its largest shareholder. &nbsp;Brent Turner, Chairman of the independent committee, said that it believes the best path forward for Surgery Partners is to continue operating as an independent publicly traded company.“We remain confident in the management team’s ability to continue delivering sustained growth and significant stockholder returns,” he said.Bain Capital put forth its proposal to acquire all of the outstanding shares of Surgery Partners not already owned by it for a cash consideration of $25.75 per share in January.Meanwhile, CEO Eric Evans on Tuesday also expressed confidence in the company achieving its full-year 2025 revenue and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) guidance.The company expects to report 2025 revenues in the range of $3.30 billion to $3.45 billion and adjusted EBITDA in the range of $555 million to $565 million for the year.Bain Capital Partners Andrew Kaplan and Devin O’Reilly also said that they remain “tremendously optimistic” about the business despite not being able to agree on the terms of the transaction.<a href="https://stocktwits.com/symbol/SGRY">SGRY stock</a> is down 6% this year and approximately 20% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-agrees-to-acquire-verve-therapeutics-for-up-to-1.3-billion/chlYyFpRRTy">Verve Therapeutics Stock Rockets 75% Pre-Market After Eli Lilly Agrees To Acquire The Company For Up To $1.3B: Retail Says Offer Is ‘Low’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Surgery Partners Stock Slumps 13% After Company Rejects Bain Capital’s Take-Private Proposal

Chairman of the Independent Committee, Brent Turner, said the best path forward for Surgery Partners is to continue operating as an independent publicly traded company.

Equity

9 Analysts Assess Surgery Partners: What You Need To Know

Latest Ratings for SGRY
 DateFirmActionFromTo Mar 2022JP MorganMaintainsNeutral Mar 2022SVB LeerinkMaintainsOutperform Mar 2022RBC CapitalMaintainsOutperform
 View More Analyst Ratings for SGRY...

What 8 Analyst Ratings Have To Say About Surgery Partners

Surgery Partners (SGRY) Poised for Upside: A Comprehensive Buy Rating Justification

In a report released on July 18, Whit Mayo from Leerink Partners reiterated a Buy rating on Surgery Partners (SGRY Research Report), with a price...

Critical Insights From Surgery Partners Analyst Ratings: What You Need To Know

While shareholders of Surgery Partners (NASDAQ:SGRY) are in the black over 5 years, those who bought a week ago aren't so fortunate

Surgery Partners, Inc. ( NASDAQ:SGRY ) shareholders might be concerned after seeing the share price drop 13% in the...

Surgery Partners: A Buy Rating Amidst Underperformance and Growth Potential

Analyst Whit Mayo of Leerink Partners reiterated a Buy rating on Surgery Partners (SGRY Research Report), retaining the price target of $47.00. W...

Surgery Partners (SGRY, $29.94) Stochastic Oscillator left the overbought zone on March 27, 2024

This is a signal that SGRY's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Surgery Partners, Inc. is healthcare services holding company, which engages in the provision of solutions for surgical and related ancillary care in support of its patients and physicians. It operates through the following business segments: Surgical Facility Services, Ancillary Services, and Optical Services. The Surgical Facility Services segment consists of the operation of ambulatory surgery centers and surgical hospitals, including anesthesia services of the company. The Ancillary Services segment operates a diagnostic laboratory and multi-specialty physician practices. The Optical Services segment involves an optical laboratory and an optical products group purchasing organization. The company was founded in 2004 and is headquartered in Brentwood, TN.

SGRY
Surgery Partners Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SGRY News

SGRY Surgery Partners Inc